vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and NOODLES & Co (NDLS). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $122.1M, roughly 1.5× NOODLES & Co). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -7.5%, a 20.8% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -4.1%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-2.8M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -1.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Noodles & Company is an American fast-casual restaurant that offers international and American noodle dishes in addition to soups and salads. Noodles & Company was founded in 1995 by Aaron Kennedy and is headquartered in Broomfield, Colorado. The company went public in 2013 and recorded a $457 million revenue in 2017. In mid-2022, there were 458 Noodles & Company locations across 31 states.
AMPH vs NDLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $122.1M |
| Net Profit | $24.4M | $-9.2M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | -5.2% |
| Net Margin | 13.3% | -7.5% |
| Revenue YoY | -1.8% | -4.1% |
| Net Profit YoY | -35.7% | 32.8% |
| EPS (diluted) | $0.51 | $-0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | — | ||
| Q3 25 | $191.8M | $122.1M | ||
| Q2 25 | $174.4M | $123.8M | ||
| Q1 25 | $170.5M | — | ||
| Q4 24 | $186.5M | $122.8M | ||
| Q3 24 | $191.2M | $127.4M | ||
| Q2 24 | $182.4M | $121.4M | ||
| Q1 24 | $171.8M | $124.3M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-9.2M | ||
| Q2 25 | $31.0M | $-9.1M | ||
| Q1 25 | $25.3M | — | ||
| Q4 24 | $38.0M | $-6.8M | ||
| Q3 24 | $40.4M | $-13.6M | ||
| Q2 24 | $37.9M | $-6.1M | ||
| Q1 24 | $43.2M | $-6.1M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | -5.2% | ||
| Q2 25 | 24.2% | -5.2% | ||
| Q1 25 | 21.9% | — | ||
| Q4 24 | 24.2% | -3.9% | ||
| Q3 24 | 29.8% | -9.0% | ||
| Q2 24 | 30.3% | -3.4% | ||
| Q1 24 | 27.9% | -3.7% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -7.5% | ||
| Q2 25 | 17.8% | -7.3% | ||
| Q1 25 | 14.8% | — | ||
| Q4 24 | 20.4% | -5.5% | ||
| Q3 24 | 21.1% | -10.7% | ||
| Q2 24 | 20.8% | -5.1% | ||
| Q1 24 | 25.1% | -4.9% |
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | $-0.20 | ||
| Q2 25 | $0.64 | $-0.20 | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | $-0.15 | ||
| Q3 24 | $0.78 | $-0.30 | ||
| Q2 24 | $0.73 | $-0.14 | ||
| Q1 24 | $0.81 | $-1.64 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $4.7M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $-38.9M |
| Total Assets | $1.6B | $280.6M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | $4.7M | ||
| Q2 25 | $231.8M | $1.4M | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | $3.3M | ||
| Q3 24 | $250.5M | $1.8M | ||
| Q2 24 | $217.8M | $1.3M | ||
| Q1 24 | $289.6M | $3.0M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | — | ||
| Q3 25 | $776.7M | $-38.9M | ||
| Q2 25 | $757.5M | $-13.9M | ||
| Q1 25 | $751.3M | — | ||
| Q4 24 | $732.3M | $3.7M | ||
| Q3 24 | $727.7M | $9.6M | ||
| Q2 24 | $713.3M | $21.9M | ||
| Q1 24 | $672.4M | $27.2M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | $280.6M | ||
| Q2 25 | $1.6B | $319.4M | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.6B | $340.5M | ||
| Q3 24 | $1.5B | $346.3M | ||
| Q2 24 | $1.5B | $360.4M | ||
| Q1 24 | $1.6B | $368.1M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $4.3M |
| Free Cash FlowOCF − Capex | $24.6M | $-2.8M |
| FCF MarginFCF / Revenue | 13.4% | -2.3% |
| Capex IntensityCapex / Revenue | 4.5% | 5.8% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-7.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | — | ||
| Q3 25 | $52.6M | $4.3M | ||
| Q2 25 | $35.6M | $4.0M | ||
| Q1 25 | $35.1M | — | ||
| Q4 24 | $29.0M | $5.8M | ||
| Q3 24 | $60.0M | $4.7M | ||
| Q2 24 | $69.1M | $7.0M | ||
| Q1 24 | $55.3M | $164.0K |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | $-2.8M | ||
| Q2 25 | $25.0M | $1.1M | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | $-1.3M | ||
| Q3 24 | $46.2M | $-4.5M | ||
| Q2 24 | $63.1M | $-1.6M | ||
| Q1 24 | $46.5M | $-15.2M |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | -2.3% | ||
| Q2 25 | 14.3% | 0.9% | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | -1.1% | ||
| Q3 24 | 24.1% | -3.5% | ||
| Q2 24 | 34.6% | -1.4% | ||
| Q1 24 | 27.1% | -12.2% |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | 5.8% | ||
| Q2 25 | 6.1% | 2.4% | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | 5.8% | ||
| Q3 24 | 7.2% | 7.2% | ||
| Q2 24 | 3.3% | 7.1% | ||
| Q1 24 | 5.1% | 12.3% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
NDLS
| Food And Beverage | $119.6M | 98% |
| Franchise | $2.5M | 2% |
